Watching Profusa, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planProfusa, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Profusa remains a clinical-stage company with unremediated material weaknesses in internal controls, now compounded by a highly conditional, dilutive proposed acquisition of G3 Vision Labs and its diagnostics subsidiaries—a business unrelated to its core biosensing focus. The acquisition requires at least $30 million in new financing, Nasdaq and stockholder approvals, and lender consents, with substantial dilution already committed (201,120 common shares and 52,903.566 preferred shares issued to sellers) regardless of whether the deal closes. Controls & Procedures disclosure changed materially (45.5%), reflecting continued internal control failures alongside the new transaction-related risk disclosures.
Red Flags Detected (7)
Internal controls over financial reporting remain not effective; material weaknesses from FY2025 10-K remain unremediated as of Q2 2026
Segregation of duties deficiency in financial statement close process persists
Company has already issued 201,120 common shares and 52,903.566 Series A preferred shares to G3 sellers even though the acquisition may never close
4 more red flags detected
Key Takeaways
Company is attempting a transformative but highly conditional acquisition outside its core competency
Shares already issued to G3 sellers regardless of deal completion represent sunk dilution
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.